The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

Published:  
03/15/2024
Categories:  
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
Image

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of the body’s own immune cells to recognize and attack melanoma cells. In this webinar, hosted by Samantha Guild, JD, President of AIM at Melanoma, we explore the implications of this newly approved treatment for melanoma care with our guest, Dr. Allison Betof Warner, MD, PhD, a leading expert in TIL therapy.

CLICK on the image below to watch

Recent Posts

Featured image for “The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public”
Jun. 09, 2026

The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public

Featured image for “Fifth Annual Evening in Memory of Valerie Guild”
Jun. 05, 2026

Fifth Annual Evening in Memory of Valerie Guild

Featured image for “Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective ”
Jun. 05, 2026

Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective 

Featured image for “Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes”
Jun. 05, 2026

Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes

Featured image for “Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors”
Jun. 05, 2026

Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors

Filter by Tag